At T2 Biosystems, our mission is to improve sepsis management by empowering clinicians to appropriately treat patients suspected of bloodstream infections faster than ever before. Early targeted therapy for pathogenic organisms may prevent bloodstream infections from progressing to sepsis. T2 Biosystems accurately identifies pathogenic organisms associated with sepsis in 3 to 5 hours without the wait of blood culture, which can take 1 to 5 or more days. T2Direct Diagnostics™ suite of products are the first FDA-cleared tests that identify pathogenic organisms directly from whole blood. Both the T2Bacteria® and T2Candida® Panels are run on the T2Dx® Instrument. Assay results provide data to clinicians helping to identify appropriate therapy faster, improve patient outcomes, advance stewardship, and reduce the cost of patient management. T2Biosystems has a strong pipeline of products in development for pathogen identification, including expanded bacterial resistance panels, a Lyme disease panel as well as direct tests from a swab for superbugs such as Candida auris.